

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.*



**邁博藥業**  
**Mabpharm Limited**  
**迈博药业有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2181)**

**CHANGE OF ADDRESS OF PRINCIPAL PLACE OF  
BUSINESS IN HONG KONG**

The board (the “**Board**”) of directors (the “**Directors**”) of Mabpharm Limited (the “**Company**”) hereby announces that the address of the principal place of business in Hong Kong of the Company has been changed to Unit 1401 of 14th Floor of Chuang’s Tower, Nos. 30-32 Connaught Road Central, Central, Hong Kong with effect from the date of this announcement.

By order of the Board  
**Mabpharm Limited**  
**Jiao Shuge**  
*Chairman*

Hong Kong, December 5, 2025

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Li Yunfeng, Mr. Tao Jing, Dr. Hou Sheng and Dr. Qian Weizhu as executive Directors; Mr. Jiao Shuge and Mr. Cen Jialin as non-executive Directors; and Dr. Zhang Yanyun, Mr. Guo Liangzhong, Mr. Leung, Louis Ho Ming and Dr. Tao Qian as independent non-executive Directors.*